ArticleCommunications biology2018
Genetically engineered human muscle transplant enhances murine host neovascularization and myogenesis.
Article in Communications biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Contractile myografts confer systemic anti-aging benefits.Nature aging · 2026Article
- Synthetic control of implanted engineered liver tissue growth.Science advances · 2026Article
- Bioprinting Perfusable and Vascularized Skeletal Muscle Flaps for the Treatment of Volumetric Muscle Loss.Advanced healthcare materials · 2025Article
- Adipogenic-Myogenic Signaling in Engineered Human Muscle Grafts used to Treat Volumetric Muscle Loss.Advanced biology · 2024Article
- Placenta-Derived Mesenchymal Stromal-Like Cells Promote 3D-Engineered Muscle Tissue Differentiation and Vessel Network Maturation.Small science · 2024Article
- Engineering Skeletal Muscle Grafts with PAX7::GFP-Sorted Human Pluripotent Stem Cell-Derived Myogenic Progenitors on Fibrin Microfiber Bundles for Tissue Regeneration.Bioengineering (Basel, Switzerland) · 2022Article
- Tri-culture of spatially organizing human skeletal muscle cells, endothelial cells, and fibroblasts enhances contractile force and vascular perfusion of skeletal muscle tissues.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Anti-Aging β-Klotho Gene-Activated Scaffold Promotes Rejuvenative Wound Healing Response in Human Adipose-Derived Stem Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Cells, scaffolds, and bioactive factors: Engineering strategies for improving regeneration following volumetric muscle loss.Biomaterials · 2021Review
- Engineering skeletal muscle: Building complexity to achieve functionality.Seminars in cell & developmental biology · 2021Review
- GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize glycemia in diabetic mice.Science advances · 2021Article
- Synergistic Effect of Biomaterial and Stem Cell for Skin Tissue Engineering in Cutaneous Wound Healing: A Concise Review.Polymers · 2021Review
- SDF-1α Gene-Activated Collagen Scaffold Restores Pro-Angiogenic Wound Healing Features in Human Diabetic Adipose-Derived Stem Cells.Biomedicines · 2021Article
- Engineering 3D skeletal muscle primed for neuromuscular regeneration following volumetric muscle loss.Biomaterials · 2020Article
- Can we mimic skeletal muscles for novel drug discovery?Expert opinion on drug discovery · 2020Article
- Vascularized and Innervated Skeletal Muscle Tissue Engineering.Advanced healthcare materials · 2020Review
- Article
- Treatment of volumetric muscle loss in mice using nanofibrillar scaffolds enhances vascular organization and integration.Communications biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered tissues are a promising tool for addressing the growing need for tissues and organs in surgical reconstructions. Prevascularization of implanted tissues is expected to enhance survival prospects post transplantation and minimize deficiencies and/or hypoxia deeper in the tissue. Here, we fabricate a three-dimensional, prevascularized engineered muscle containing human myoblasts, genetically modified endothelial cells secreting angiopoietin 1 (ANGPT1) and genetically modified smooth muscle cells secreting vascular endothelial growth factor (VEGF). The genetically engineered human muscle shows enhanced host neovascularization and myogenesis following transplantation into a mouse host, compared to the non-secreting control. The vascular, genetically modified cells have been cleared for clinical trials and can be used to construct autologous vascularized tissues. Therefore, the described genetically engineered vascularized muscle has the potential to be fully translated to the clinical setting to overcome autologous tissue shortage and to accelerate host neovascularization and integration of engineered grafts following transplantation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.